BMC Nephrology
Elnaz Roohi and Donna Rahmatian and Megan Borkum and Nina Bredenkamp and Claudia Ho and Hilary Wu and Katie Haubrich and Adam Pietrobon and Sarah Gregson and Mohammad Atiquzzaman and Adeera Levin
DOI: 10.1186/s12882-025-04734-801 / 2026
Pediatric Transplantation
Iona Berger and Mina Matsuda-Abedini and Kathryn Haubrich
DOI: 10.1111/petr.7014309 / 2025
Pediatric Transplantation
Kathryn Haubrich and Katherine Broad and Tatsuma Hind and Tom Blydt-Hansen
DOI: 10.1111/petr.7001202 / 2025
Journal of the Association of Medical Microbiology and Infectious Disease Canada
Kathryn Haubrich and Cherry Mammen and Inna Sekirov and Hana Mitchell
DOI: 10.3138/jammi-2021-002906 / 2022
Pediatric Research
DOI: 10.1038/s41390-019-0523-404 / 2020
Pediatric Transplantation
Iona Berger and Kathryn Haubrich and Mary H. H. Ensom and Roxane Carr
DOI: 10.1111/petr.1335503 / 2019
Pediatric Transplantation
Kathryn Haubrich and Soren Gantt and Tom Blydt-Hansen
DOI: 10.1111/petr.1318606 / 2018
Mycophenolate is commonly used as an immunosuppressant in children who have received solid organ transplants to prevent rejection of the graft. Currently therapeutic drug monitoring is recommended as dosage and serum concentration do not correlate well however it is unclear from the literature what the upper limit of the therapeutic range should be and if limited sampling strategies to estimate area under the curve correlates to effectiveness and adverse drug reactions. Objective: To describe the correlation between limited sampling strategy for mycophenolate and clinical effectiveness (adverse drug reactions and signs or organ graft rejection).
Recombinant human growth hormone (rhGH) has been shown to support linear growth in children with chronic kidney disease. However, optimal dosing and duration of therapy remains poorly described. Objective: to describe the effectiveness of rhGH therapy on height velocity and height standard deviation score, stratifying by primary renal disease, and the incidence of adverse effects in children managed on rhGH therapy.
At BC Children’s, we are making discoveries that save lives and transform health care for children in our province and around the world. Our research portfolio includes basic, clinical, population, and public health research.
EXPLORE OUR RESEARCH
Sign up for compelling stories about innovative science, the doctors and researchers who turn ideas into discoveries and treatments, and the kids and families whose lives are changed.
BC Children's Hospital Research Institute operates on the ancestral and unceded territory of the Coast Salish peoples — xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh) Nations. Further, this acknowledgement, gratitude, and respect extends to all of the First Nations communities on whose territories the Research Institute builds relationships and operates in British Columbia.
© 2026 BC Children’s Hospital Research Institute. All rights reserved.
Crafted with by Forge and Smith
